Skip to content
OpenCapital
Get started

Pfizer PFE Paxlovid and Comirnaty — Deferred revenues

Similar metrics at other companies

4D Molecular Therapeutics logo
FDMTDeferred Revenue — Deferred Revenue
$2.49M—
Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Deferred Revenue
$2.5M—
Nuvation Bio logo
NUVBProduct Revenue — Deferred Revenue
$100K—
IBT
IBTADeferred revenue — Deferred Revenue
$2.7M-51.8%
PTC Therapeutics logo
PTCTProduct — Deferred Revenue
$0—
Perspective Therapeutics logo
CATXDeferred income
$26.6M0.0%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$134.91B-1.0%
Enterprise value$197.57B+0.7%
P/E11.1×—
P/S2.1×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's paxlovid and comirnaty — deferred revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's paxlovid and comirnaty — deferred revenues?
Pfizer (PFE) reported paxlovid and comirnaty — deferred revenues of $1.5B in Q1 2026.
How has Pfizer's paxlovid and comirnaty — deferred revenues changed year-over-year?
Pfizer's paxlovid and comirnaty — deferred revenues decreased by 21.1% year-over-year, from $1.9B to $1.5B.
What does paxlovid and comirnaty — deferred revenues mean?
This represents the total amount of consideration received from customers for which the performance obligations related to specific pharmaceutical products have not yet been satisfied. It reflects advance payments or billings for products where control has not yet transferred to the buyer. This is a critical indicator of future revenue visibility for high-demand therapeutic products.